

Reimbursement Policy

Prostate Biopsy Specimen Analysis

[POLICY DESCRIPTION](#) | [INDICATIONS AND/OR LIMITATIONS OF COVERAGE](#) | [APPLICABLE STATE AND FEDERAL REGULATIONS](#) | [APPLICABLE CPT/HCPCS PROCEDURE CODES](#) | [EVIDENCE-BASED SCIENTIFIC REFERENCES](#) | [REVISION HISTORY](#)

I. Policy Description

Prostate cancer is characterized by a malignancy of the small walnut-shaped gland that produces seminal fluid. This malignancy can present with a wide clinical range, from only being a microscopic, well-differentiated tumor that may never be clinically significant all the way to being an aggressive, high-grade cancer.¹

II. Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in the "Applicable State and Federal Regulations" section of this policy document.

- 1) In the initial diagnosis of prostate cancer as a follow-up to abnormal PSA results, presence of a palpable nodule on digital rectal examination, **or** suspicious radiologic findings, pathological examination of tissue obtained from a prostate biopsy involving 12 core extended sampling (see Note 1 below) **MEETS COVERAGE CRITERIA**.
- 2) When the clinical suspicion of prostate cancer remains in an individual for whom an initial biopsy was negative for prostate cancer, pathological examination of tissue from a follow-up prostate biopsy (excluding prostate saturation biopsy) **MEETS COVERAGE CRITERIA**.

The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of an individual's illness.

- 3) Pathological examination of tissue obtained from a prostate saturation biopsy **DOES NOT MEET COVERAGE CRITERIA** for the diagnosis, staging, or management of prostate cancer.
-

Reimbursement Policy

NOTES:

Note 1: One vial per sextant, with no more than two core samples per vial. Each vial, regardless of the number of cores enclosed, is considered a single specimen for billing purposes.

III. Applicable State and Federal Regulations

DISCLAIMER: If there is a conflict between this policy and any relevant, applicable government policy for a particular member [e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the Medicare search website: <https://www.cms.gov/medicare-coverage-database/search.aspx>. For the most up-to-date Medicaid policies and coverage, visit the applicable state Medicaid website.

Food and Drug Administration (FDA)

The FDA has cleared numerous devices including needles, reagents, instrumentation, and imaging systems for use in prostate biopsy. Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

IV. Applicable CPT/HCPCS Procedure Codes

CPT	Code Description
88305	Level IV – Surgical pathology, gross and microscopic examination
G0416	Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method

Current Procedural Terminology© American Medical Association. All Rights reserved.

Procedure codes appearing in Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

V. Evidence-based Scientific References

1. Taplin M-E, Smith J. Clinical presentation and diagnosis of prostate cancer - UpToDate. Updated March 22, 2024. <https://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-prostate-cancer>

Reimbursement Policy

2. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. *CA Cancer J Clin.* Jan-Feb 2025;75(1):10-45. doi:10.3322/caac.21871
3. Bell KJ, Del Mar C, Wright G, Dickinson J, Glasziou P. Prevalence of incidental prostate cancer: A systematic review of autopsy studies. *International journal of cancer.* Oct 01 2015;137(7):1749-57. doi:10.1002/ijc.29538
4. Hoffman R, ., Preston M. Screening for prostate cancer. Updated Jun 18, 2025. <https://www.uptodate.com/contents/screening-for-prostate-cancer>
5. Gosselaar C, Roobol MJ, Roemeling S, Wolters T, van Leenders GJ, Schroder FH. The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer. *BJU international.* Mar 2008;101(6):685-90. doi:10.1111/j.1464-410X.2007.07309.x
6. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. *The Journal of urology.* Jul 1989;142(1):71-4; discussion 74-5.
7. Benway B, Andriole G. Prostate biopsy. Updated August 7, 2024. <https://www.uptodate.com/contents/prostate-biopsy>
8. Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. *The Journal of urology.* May 2006;175(5):1605-12. doi:10.1016/s0022-5347(05)00957-2
9. Pepe P, Aragona F. Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. *Urology.* Dec 2007;70(6):1131-5. doi:10.1016/j.urology.2007.07.068
10. Thompson JE, Hayen A, Landau A, et al. Medium-term oncological outcomes for extended vs saturation biopsy and transrectal vs transperineal biopsy in active surveillance for prostate cancer. *BJU international.* Jun 2015;115(6):884-91. doi:10.1111/bju.12858
11. Zaytoun OM, Moussa AS, Gao T, Fareed K, Jones JS. Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population. *The Journal of urology.* Sep 2011;186(3):850-4. doi:10.1016/j.juro.2011.04.069
12. Brown LC, Ahmed HU, Faria R, et al. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. *Health technology assessment (Winchester, England).* Jul 2018;22(39):1-176. doi:10.3310/hta22390
13. Sidana A, Watson MJ, George AK, et al. Fusion prostate biopsy outperforms 12-core systematic prostate biopsy in patients with prior negative systematic biopsy: A multi-institutional analysis. *Urologic oncology.* Jul 2018;36(7):341.e1-341.e7. doi:10.1016/j.urolonc.2018.04.002
14. Pepe P, Garufi A, Priolo GD, Galia A, Fraggetta F, Pennisi M. Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with 1,032 Men Who Underwent Prostate Biopsy. *The Journal of urology.* Oct 2018;200(4):774-778. doi:10.1016/j.juro.2018.04.061
15. Pepe P, Pennisi M, Fraggetta F. How Many Cores Should be Obtained During Saturation Biopsy in the Era of Multiparametric Magnetic Resonance? Experience in 875 Patients

Reimbursement Policy

- Submitted to Repeat Prostate Biopsy. *Urology*. Mar 2020;137:133-137.
doi:10.1016/j.urology.2019.11.016
16. Klotz L, Chin J, Black PC, et al. Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial. *JAMA Oncol*. Apr 1 2021;7(4):534-542. doi:10.1001/jamaoncol.2020.7589
 17. Lokeshwar SD, Nguyen J, Rahman SN, et al. Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer. *Urologic oncology*. Sep 2022;40(9):407.e21-407.e27.
doi:10.1016/j.urolonc.2022.06.005
 18. Pier Paolo A, Andrea P, Cesare S, et al. Enhanced diagnostic accuracy of micro-ultrasound in prostate cancer detection: An updated series from a single-center prospective study. *Urologic Oncology: Seminars and Original Investigations*. 2025;doi:10.1016/j.urolonc.2025.03.012
 19. Bjurlin MA, Carter HB, Schellhammer P, et al. Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. *The Journal of urology*. Jun 2013;189(6):2039-46. doi:10.1016/j.juro.2013.02.072
 20. Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options. *The Journal of urology*. Apr 2018;199(4):990-997.
doi:10.1016/j.juro.2018.01.002
 21. Bekelman JE, Rumble RB, Chen RC, et al. Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. *Journal of Clinical Oncology*. 2018/11/10 2018;36(32):3251-3258. doi:10.1200/JCO.18.00606
 22. Bjurlin MA, Carroll PR, Eggener S, et al. Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. *The Journal of urology*. Apr 2020;203(4):706-712.
doi:10.1097/ju.0000000000000617
 23. Wei JT, Barocas D, Carlsson S, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy. *The Journal of urology*. Apr 25 2023;101097ju00000000000003492. doi:10.1097/ju.00000000000003492
 24. Feuer Z, Tan H-J, Nielsen ME. AUA SPOTLIGHT Advancing Diagnostic Excellence in Prostate Cancer: Insights From the Quality Summit on Prostate MRI. American Urological Association. Updated May 1, 2025. <https://auanews.net/issues/articles/2025/may-2025/aua-spotlight-advancing-diagnostic-excellence-in-prostate-cancer-insights-from-the-quality-summit-on-prostate-mri>
 25. NCCN. NCCN Clinical Practice Guidelines in Oncology; Prostate Cancer Early Detection. NCCN. Updated March 11, 2025. v2.
https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf
 26. NCCN. NCCN Clinical Practice Guidelines in Oncology; Prostate Cancer. Updated April 16, 2025. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

Reimbursement Policy

27. Coakley FV, Oto A, Alexander LF, et al. ACR Appropriateness Criteria((R)) Prostate Cancer-Pretreatment Detection, Surveillance, and Staging. *Journal of the American College of Radiology : JACR*. May 2017;14(5s):S245-s257. doi:10.1016/j.jacr.2017.02.026
28. Akin O, Woo S, Oto A, et al. ACR Appropriateness Criteria® Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2022 Update. *Journal of the American College of Radiology*. 2023;20(5):S187-S210.
29. Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. *CA Cancer J Clin*. Mar-Apr 2010;60(2):70-98. doi:10.3322/caac.20066
30. Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. *CA: A Cancer Journal for Clinicians*. 2019/05/01 2019;69(3):184-210. doi:10.3322/caac.21557
31. USPSTF. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. *JAMA*. 2018;319(18):1901-1913. doi:10.1001/jama.2018.3710
32. Parker C, Castro E, Fizazi K, et al. Prostate Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*. 2020;doi:10.1016/j.annonc.2020.06.011
33. EAU. Prostate Cancer. <https://uroweb.org/guidelines/prostate-cancer/panel>

VI. Revision History

Revision Date	Summary of Changes
09/04/2025	Reviewed and Updated: Updated the background, guidelines and recommendations, and evidence-based scientific references. Literature review did not necessitate any modifications to coverage criteria. The following changes were made for clarity and consistency: Note 1, added “Each vial, regardless of the number of cores enclosed, is considered a single specimen for billing purposes.” for clarity on unit restrictions for prostate biopsy.